World Journal of Urology

, Volume 26, Issue 1, pp 19–24 | Cite as

Long-term outcome of home dipstick testing for hematuria

  • Ralph Madeb
  • Edward M. MessingEmail author
Topic Paper


The most common symptom of bladder cancer (BC) is hematuria and microhematuria will occur in virtually all patients with BC if one tests for it frequently enough. However, hematuria even when caused by serious disease, often is intermittent, and once above some threshold the degree of microhematuria is unrelated to the seriousness of its underlying cause. Based on these principles a BC screening study was conducted to determine if repetitive hematuria testing can detect BC early and whether this resulted in reduced BC mortality, in long-term follow-up compared with disease related outcomes of a contemporary unscreened population similar to the one taking part in screening. The study and the long-term outcomes are reviewed. At 14 years minimum follow-up, none of the 21 men diagnosed with BC by hematuria screening have died of the disease; 12 were still alive and 9 had died of diseases other than BC, with a median survival of 8.8 years. The lower overall mortality in screenees with BC was primarily because of the reduced mortality from BC in that group. Screening had effected a shift of the high grade tumors to earlier (more superficial) stages at diagnosis.


Bladder cancer Screening Urinary markers Microhematuria 


  1. 1.
    Messing EM (2007) Urothelial tumors of the urinary tract. In: Walsh PC et al (eds) Campbell’s urology, vol 9. WB Saunders, Philadelphia, pp 2407–2446Google Scholar
  2. 2.
    Madeb R, Golijanin D, Stephenson L et al (2006) Long-term outcome of patients with a negative work-up for asymptomatic microhematuria (MH). J Urol 175(4 Suppl):285Google Scholar
  3. 3.
    Messing EM, Vaillancourt A (1990) Hematuria screening for bladder cancer. J Occup Med 32(9):838–845PubMedCrossRefGoogle Scholar
  4. 4.
    Carson CC III, Segura JW, Greene LF (1979) Clinical importance of microhematuria. JAMA 241(2):149–150PubMedCrossRefGoogle Scholar
  5. 5.
    Messing EM, Young TB, Hunt VB et al (1987) The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol 137(5):919–922PubMedGoogle Scholar
  6. 6.
    Messing EM, Young TB, Hunt VB et al (1989) Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer 64(11):2361–2367PubMedCrossRefGoogle Scholar
  7. 7.
    Messing EM, Young TB, Hunt VB et al (1992) Home screening for hematuria: results of a multiclinic study. J Urol 148(2 Pt 1):289–292PubMedGoogle Scholar
  8. 8.
    Maessing EM, Young TB, Hunt VB et al (1995) Hematuria home screening: repeat testing results. J Urol 154(1):57–61CrossRefGoogle Scholar
  9. 9.
    Messing EM, Young TB, Hunt VB et al (1995) Hematuria home screening: repeat testing results. J Urol 154(1):57–61PubMedCrossRefGoogle Scholar
  10. 10.
    Britton JP, Dowell AC, Whelan P (1989) Dipstick haematuria and bladder cancer in men over 60: results of a community study. BMJ 299(6706):1010–1012PubMedCrossRefGoogle Scholar
  11. 11.
    Britton JP, Dowell AC, Whelan P et al (1992) A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 148(3):788–790PubMedGoogle Scholar
  12. 12.
    Messing EM, Young TB, Hunt VB et al (1995) Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3):387–396PubMedCrossRefGoogle Scholar
  13. 13.
    Messing EM, Madeb R, Young T et al (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9):2173–2179PubMedCrossRefGoogle Scholar
  14. 14.
    Thorstenson AG, Larsson H, Wijkstrom H (2003) Bladder cancer characteristics in a population based study of newly detected tumors. J Urol 169(4):223 (abstract)Google Scholar
  15. 15.
    Madeb R, Messing EM (2004) Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 22(2):86–92PubMedGoogle Scholar
  16. 16.
    Cai T, Bartoletti R (2007) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 109(9):1923–1924PubMedCrossRefGoogle Scholar
  17. 17.
    Grossman HB, Messing E, Soloway M et al (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810–816PubMedCrossRefGoogle Scholar
  18. 18.
    Grossman HB, Soloway M, Messing E et al (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299–305PubMedCrossRefGoogle Scholar
  19. 19.
    Lokeshwar VB, Soloway MS (2001) Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 165(4):1067–1077PubMedCrossRefGoogle Scholar
  20. 20.
    Lokeshwar VB, Habuchi T, Grossman HB et al (2005) Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl 1):35–63PubMedCrossRefGoogle Scholar
  21. 21.
    Lokeshwar VB, Selzer MG (2006) Urinary bladder tumor markers. Urol Oncol 24(6):528–537PubMedGoogle Scholar
  22. 22.
    Grossman HB, Blute ML, Dinney CP et al (2006) The use of urine-based biomarkers in bladder cancer. Urology 67(3 Suppl 1):62–64PubMedCrossRefGoogle Scholar
  23. 23.
    Messing E (2007) Markers of detection. Urol Oncol 25(4):344–347PubMedGoogle Scholar
  24. 24.
    Schmitz-Drager BJ, Beiche B, Tirsar LA et al (2007) Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 51(6):1582–1588PubMedCrossRefGoogle Scholar
  25. 25.
    Boman H, Hedelin H, Jacobsson S et al (2002) Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 168(5):1955–1959PubMedCrossRefGoogle Scholar
  26. 26.
    Messing EM (2006) Bladder tumor markers. J Urol 175(4):1195–1196PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Urology, Strong Memorial HospitalUniversity of Rochester School of MedicineRochesterUSA

Personalised recommendations